XSpray Microparticles receives 18 million SEK investment to finance clinical development of its lead compound XS004
As previously announced from Karolinska Development AB, XSpray Microparticles AB will receive 18 million SEK from a consortium led by The Foundation for Baltic and East European Studies (Östersjöstiftelsen) and Recipharm Venture Fund.The 18 million SEK investment will be used to finance the clinical development of XSpray’s lead compound, XS004, developed with XSpray’s proprietary HyNap™ drug formulation technology. XS004 is based on a well-known protein kinase inhibitor (PKI) compound. It is anticipated that these funds will finance XS004 through the Phase 1 clinical trial, results of